Drug intelligence / Profile preview

YHC1161

Development stage: Preclinical
Lead developer: Yuhan

Overview

YHC1161 is an early-stage therapeutic candidate being developed by Yuhan for the treatment of obesity. Part of Yuhan's internal pipeline of metabolic and endocrine therapies, the drug is currently in the preclinical or discovery phase of development. While specific details regarding its biological target and mechanism of action have not been publicly disclosed, it is part of Yuhan's broader strategy to expand its obesity portfolio beyond traditional GLP-1 receptor agonists, which includes exploring novel targets such as GDF15 and G-protein coupled receptors (GPCRs).

Beyond the preview

Go deeper on YHC1161.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YHC1161.

Explore the full profile